Cervical cancer is one of the most common cancers threatening women's health, and the
persistent infection of high-risk human papillomavirus (HPV) is closely related to the …

Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical
cancer and other malignant cancers. Although early detection and treatment can be …

The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use
of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human …

Highlights•VLP have been engineered to improve their utility as vaccine platforms.•Targeted
engineering of VLPs has enhanced immunogenicity, stability, and versatility.•Predictive …

Introduction: Virus-like particle (VLP) vaccines face significant challenges in their translation
from laboratory models, to routine clinical administration. While some VLP vaccines thrive …

The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major
papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe …

Cervical cancer is an important public health problem worldwide, and especially in
developing countries. The link between cervical cancer and oncogenic human …

Licensed human papillomavirus (HPV) vaccines contain virus-like particles (VLPs) self-
assembled from L1 major-capsid proteins that are remarkably effective prophylactic …

Virus-like particles (VLP) spontaneously assemble from viral structural proteins. They are
naturally biocompatible and non-infectious. VLP can serve as a platform for many potential …